Aldeyra Therapeutics (ALDX) Cash & Equivalents (2013 - 2026)

Aldeyra Therapeutics' Cash & Equivalents history runs 14 years deep, the most recent figure standing at $40.9 million for Q1 2026.

• Quarterly Cash & Equivalents fell 18.87% year-over-year to $40.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.9 million (down 18.87% YoY) and the FY2025 annual result came in at $70.0 million, up 28.45% from the prior year.
• Cash & Equivalents was $40.9 million for Q1 2026 at Aldeyra Therapeutics, down from $70.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $165.0 million in Q1 2023 and bottomed at $14.3 million in Q4 2023.
• A 5-year average of $79.3 million and a median of $55.0 million in 2025 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2023 — Cash & Equivalents tumbled 90.09% — and 2024, when it soared 280.97%.
• Aldeyra Therapeutics' Cash & Equivalents stood at $144.4 million in 2022, then tumbled by 90.09% to $14.3 million in 2023, then surged by 280.97% to $54.5 million in 2024, then gained by 28.45% to $70.0 million in 2025, then tumbled by 41.67% to $40.9 million in 2026.
• Business Quant data shows ALDX's Cash & Equivalents at $40.9 million in Q1 2026, $70.0 million in Q4 2025, and $55.0 million in Q3 2025.